Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives

References

• DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007 May;245(5):755–762.
   PubMed Web of Science ®Google Scholar
• Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012 Jun;30(16):1934–1940.
   PubMed Web of Science ®Google Scholar
• Ghidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB (Oxford). 2017 09;19(9):741–748.
   PubMed Web of Science ®Google Scholar
• Ma N, Cheng H, Qin B, et al. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer. 2015;15:615.
   PubMed Web of Science ®Google Scholar
• Ma KW, Cheung TT, Leung B, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis. Medicine (Baltimore). 2019 Feb;98(5):e14013.
   PubMed Web of Science ®Google Scholar
• Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002 Oct;95(8):1685–1695.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul;308(2):147–156.
   PubMed Web of Science ®Google Scholar
• Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018 02;105(3):192–202.
   PubMed Web of Science ®Google Scholar
• Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019 Mar;37(8):658–667.
   PubMed Web of Science ®Google Scholar
• Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015 Jul;15:564.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Nagano H, Tomokuni A, et al. A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Ann Surg. 2019 Aug;270(2):230–237.
   Web of Science ®Google Scholar
• Nakachi K, Konishi M, Ikeda M, et al. A randomized phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan clinical oncology group study (JCOG1202, ASCOT). Jpn J Clin Oncol. 2018 Apr;48(4):392–395.
   PubMed Web of Science ®Google Scholar
• Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 May;20(5):663–673.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019 Apr;37(12):1015–1027.
   PubMed Web of Science ®Google Scholar
• Shinohara ET, Mitra N, Guo M, et al. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2008 Dec;72(5):1495–1501.
   PubMed Web of Science ®Google Scholar
• Bonet Beltrán M, Allal AS, Gich I, et al. Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies. Cancer Treat Rev. 2012 Apr;38(2):111–119.
   PubMed Web of Science ®Google Scholar
• Kim BH, Kwon J, Chie EK, et al. Adjuvant chemoradiotherapy is associated with improved survival for patients with resected gallbladder carcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018 Jan;25(1):255–264.
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015 Aug;33(24):2617–2622.
   PubMed Web of Science ®Google Scholar
• Mamadgi J, Babar L, Lundeen K, et al. Retrospective analysis of outcomes with different adjuvant treatments in cholangiocarcinoma: an NCDB review [abstract]. J Clin Oncol. 2019;37(15_suppl):e15677–e15677.
   Web of Science ®Google Scholar
• Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v28–v37.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996 Aug;7(6):593–600.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998 Jun;9(6):653–656.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Van Cutsem E, Van Laethem JL, et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005 Feb;41(3):398–403.
   PubMed Web of Science ®Google Scholar
• Ghidini M, Pizzo C, Botticelli A, et al. Biliary tract cancer: current challenges and future prospects. Cancer Manag Res. 2019;11:379–388.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Palmer D, et al. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer. 2016 04;114(9):965–971.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010 Aug;103(4):469–474.
   PubMed Web of Science ®Google Scholar
• Ahn DH, Reardon J, Ahn CW, et al. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. Int J Cancer. 2018 04;142(8):1671–1675.
   PubMed Web of Science ®Google Scholar
• Dierks J, Gaspersz MP, Belkouz A, et al. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta Oncol. 2018 Jun;57(6):807–812.
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012 Feb;13(2):181–188.
   PubMed Web of Science ®Google Scholar
• Sharma A, Mohanti B, Raina V, et al. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol. 2010 Feb;65(3):497–502.
   PubMed Web of Science ®Google Scholar
• André T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008 Sep;99(6):862–867.
   PubMed Web of Science ®Google Scholar
• André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004 Sep;15(9):1339–1343.
   PubMed Web of Science ®Google Scholar
• Fiteni F, Nguyen T, Vernerey D, et al. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 2014 Dec;3(6):1502–1511.
   PubMed Web of Science ®Google Scholar
• McNamara MG, Bridgewater J, Lopes A, et al. Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer. 2017 04;17(1):262.
   PubMedGoogle Scholar
• Horgan A, Knox J, Aneja P, et al. Patterns of care and treatment outcomes in older patients with biliary tract cancer. Oncotarget. 2015 Dec;6(42):44995–45004.
   PubMedGoogle Scholar
• Song W, Zhu ZG, Wu Q, et al. A nomogram to predict overall survival for biliary tract cancer. Cancer Manag Res. 2018;10:1535–1541.
   PubMed Web of Science ®Google Scholar
• Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014 Feb;25(2):391–398.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Wasan H, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016 Jan;27(1):134–140.
   PubMed Web of Science ®Google Scholar
• McNamara MG, Templeton AJ, Maganti M, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014 Jun;50(9):1581–1589.
   PubMed Web of Science ®Google Scholar
• Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol. 2014 Dec;5(6):428–432.
   PubMedGoogle Scholar
• Kim BJ, Hyung J, Yoo C, et al. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol. 2017 Jul;80(1):209–215.
   PubMed Web of Science ®Google Scholar
• Okuno M, Ebata T, Yokoyama Y, et al. Appraisal of inflammation-based prognostic scores in patients with unresectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2016 Oct;23(10):636–642.
   PubMed Web of Science ®Google Scholar
• Zhou LH, Luo XF. Platelet to lymphocyte ratio in biliary tract cancer: review and meta-analysis. Clin Chim Acta. 2017 Nov;474:102–107.
   PubMed Web of Science ®Google Scholar
• Grenader T, Nash S, Plotkin Y, et al. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. Ann Oncol. 2015 Sep;26(9):1910–1916.
   PubMed Web of Science ®Google Scholar
• Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17(Suppl 5):v7–12.
   PubMed Web of Science ®Google Scholar
• Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998 Oct;58(19):4349–4357.
   PubMed Web of Science ®Google Scholar
• Saiki Y, Yoshino Y, Fujimura H, et al. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem Biophys Res Commun. 2012 Apr;421(1):98–104.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Clarke ML, Jordheim L, et al. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol. 2004;4:8.
   PubMedGoogle Scholar
• Kroep JR, Loves WJ, van der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther. 2002 Apr;1(6):371–376.
   PubMed Web of Science ®Google Scholar
• Slusarczyk M, Lopez MH, Balzarini J, et al. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem. 2014 Feb;57(4):1531–1542.
   PubMed Web of Science ®Google Scholar
• Blagden SP, Rizzuto I, Suppiah P, et al. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. Br J Cancer. 2018 Oct;119(7):815–822.
   PubMed Web of Science ®Google Scholar
• McNamara MG, Bridgewater J, Palmer D, et al. combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08) [abstract]. Ann Oncol. 2018;29(suppl_8):viii259.
   Google Scholar
• Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol. 2001 Sep;12(9):1247–1254.
   PubMed Web of Science ®Google Scholar
• Schinzari G, Rossi E, Mambella G, et al. First-line treatment of advanced biliary ducts carcinoma: a randomized phase II study evaluating 5-FU/LV plus oxaliplatin (Folfox 4). Anticancer Res. 2017 09;37(9):5193–5197.
   PubMed Web of Science ®Google Scholar
• Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005 Apr;23(10):2332–2338.
   PubMed Web of Science ®Google Scholar
• Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol. 2001 Oct;19(20):4089–4091.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Isayama H, Nakai Y, et al. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol. 2013 Apr;71(4):973–979.
   PubMed Web of Science ®Google Scholar
• Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan clinical oncology group trial (JCOG 0805). Cancer Sci. 2013 Sep;104(9):1211–1216.
   PubMed Web of Science ®Google Scholar
• Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: a Japan clinical oncology group study (JCOG1113, FUGA-BT) [abstract]. J Clin Oncol. 2018;36(4_suppl):205.
   Web of Science ®Google Scholar
• Jensen LH, Lindebjerg J, Ploen J, et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol. 2012 Sep;23(9):2341–2346.
   PubMed Web of Science ®Google Scholar
• Sohn BS, Yuh YJ, Kim KH, et al. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater. Tumori. 2013 Mar-Apr;99(2):139–144.
   PubMed Web of Science ®Google Scholar
• Davis EJ, Griffith KA, Kim EJ, et al. A phase II study of biweekly cisplatin, fixed-dose-rate gemcitabine and infusional 5-fluorouracil in patients with metastatic pancreatic and biliary cancers. Am J Clin Oncol. 2018 02;41(2):128–132.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Taketomi A, Itoh S, et al. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. Jpn J Clin Oncol. 2010 Jan;40(1):24–28.
   PubMed Web of Science ®Google Scholar
• Sakai D, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA) [abstract]. Ann Oncol. 2018;29(suppl_8):viii205–viii270.
   Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068–3077.
   PubMed Web of Science ®Google Scholar
• Kim ST, Kang JH, Lee J, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol. 2019 May 1;30(5):788–795.
   PubMed Web of Science ®Google Scholar
• Frese KK, Neesse A, Cook N, et al. nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012 Mar;2(3):260–269.
   PubMed Web of Science ®Google Scholar
• Chang PM, Cheng CT, Wu RC, et al. Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. Oncol Lett. 2018 Jul;16(1):566–572.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018 Dec;4(12):1707–1712.
   PubMed Web of Science ®Google Scholar
• Kim JY, Do YR, Song HS, et al. Multicenter phase ii clinical trial of genexol-PM® with gemcitabine in advanced biliary tract cancer. Anticancer Res. 2017 03;37(3):1467–1473.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019 Jun 1;5(6):824–830.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Rauthan A, Patil P. Modified FOLFIRINOX regimen in advanced biliary tract adenocarcinoma [abstract]. J Clin Oncol. 2017;35(4_suppl):484.
   Web of Science ®Google Scholar
• Ulusakarya A, Karray W, Abdou J, et al. FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC) [abstract]. Ann Oncol. 2018;29(suppl_8):viii260.
   Google Scholar
• Phelip JM, Edeline J, Blanc JF, et al. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II/III study. Dig Liver Dis. 2019 02;51(2):318–320.
   PubMedGoogle Scholar
• Brieau B, Dahan L, De Rycke Y, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the association des gastro-entérologues oncologues. Cancer. 2015 Sep;121(18):3290–3297.
   PubMed Web of Science ®Google Scholar
• Takahara N, Nakai Y, Isayama H, et al. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases. Invest New Drugs. 2018 12;36(6):1093–1102.
   PubMed Web of Science ®Google Scholar
• Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer. 2013 Jan;49(2):329–335.
   PubMed Web of Science ®Google Scholar
• Moik F, Riedl JM, Winder T, et al. Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: a propensity score analysis. Sci Rep. 2019 Apr;9(1):5548.
   PubMedGoogle Scholar
• Lamarca A, Hubner RA, David Ryder W, et al. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014 Dec;25(12):2328–2338.
   PubMed Web of Science ®Google Scholar
• Schweitzer N, Kirstein MM, Kratzel AM, et al. Second line chemotherapy in biliary tract cancer: outcome and prognostic factors. Liver Int. 2019 May;39(5):914–923.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Singh Wasan H, et al. ABC-06: a randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy [abstract]. J Clin Oncol. 2019;37(15_suppl):4003.
   Web of Science ®Google Scholar
• Kim BJ, Yoo C, Kim KP, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017 Feb;116(5):561–567.
   PubMed Web of Science ®Google Scholar
• Ying J, Chen J. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: a comprehensive meta-analysis of published data. Crit Rev Oncol Hematol. 2019 Jul;139:134–142.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Tu X, Zhao P, et al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer. 2018 Aug;119(3):291–295.
   PubMed Web of Science ®Google Scholar
• Guion-Dusserre JF, Lorgis V, Vincent J, et al. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol. 2015 Feb;21(7):2096–2101.
   PubMed Web of Science ®Google Scholar
• Ramaswamy A, Ostwal V, Pande N, et al. Second-line palliative chemotherapy in advanced gall bladder cancer, CAP-IRI: safe and effective option. J Gastrointest Cancer. 2016 Sep;47(3):305–312.
   PubMedGoogle Scholar
• Sebbagh S, Roux J, Dreyer C, et al. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. Acta Oncol. 2016 Sep-Oct;55(9–10):1168–1174.
   PubMed Web of Science ®Google Scholar
• Filippi R, Lombardi P, Depetris I, et al. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. Expert Opin Pharmacother. 2018 09;19(13):1451–1463.
   PubMed Web of Science ®Google Scholar
• Tajima H, Ohta T, Shinbashi H, et al. Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer. Mol Clin Oncol. 2017 May;6(5):753–757.
   PubMed Web of Science ®Google Scholar
• Dadduzio V, Rizzato MD, Ramondo G, et al. Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): outcomes and safety from a multicenter Italian experience [abstract]. Ann Oncol. 2018;29(suppl_8):viii261.
   Google Scholar
• Lischalk JW, Repka MC, Unger K. Radiation therapy for hepatobiliary malignancies. J Gastrointest Oncol. 2017 Apr;8(2):279–292.
   PubMed Web of Science ®Google Scholar
• Verma V, Kusi Appiah A, Lautenschlaeger T, et al. Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base. J Gastrointest Oncol. 2018 Jun;9(3):527–535.
   PubMed Web of Science ®Google Scholar
• Takahashi EA, Kinsman KA, Schmit GD, et al. Thermal ablation of intrahepatic cholangiocarcinoma: safety, efficacy, and factors affecting local tumor progression. Abdom Radiol (NY). 2018 Dec;43(12):3487–3492.
   PubMed Web of Science ®Google Scholar
• Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016 Mar;122(5):758–765.
   PubMed Web of Science ®Google Scholar
• Cercek A, Kemeny NE, Boerner T, et al. A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC) [abstract]. J Clin Oncol. 2018;36(15_suppl):4092.
   Web of Science ®Google Scholar
• Marquardt S, Kirstein MM, Brüning R, et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol. 2019 Apr;29(4):1882–1892.
   PubMed Web of Science ®Google Scholar
• Falkenstein TA, Götze TO, Ouaissi M, et al. First clinical data of pressurized intraperitoneal aerosol chemotherapy (PIPAC) as salvage therapy for peritoneal metastatic biliary tract cancer. Anticancer Res. 2018 01;38(1):373–378.
   PubMed Web of Science ®Google Scholar
• Lombardi P, Marino D, Fenocchio E, et al. Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opin Emerg Drugs. 2018 03;23(1):63–75.
   PubMed Web of Science ®Google Scholar
• Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017 10;7(10):1116–1135.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015 Sep;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013 Apr;144(4):829–840.
   PubMed Web of Science ®Google Scholar
• Nepal C, O’Rourke CJ, Oliveira DVNP, et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology. 2018 09;68(3):949–963.
   PubMed Web of Science ®Google Scholar
• Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5:5696.
   PubMed Web of Science ®Google Scholar
• Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018 05;68(5):959–969.
   PubMed Web of Science ®Google Scholar
• Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012 Oct;43(10):1552–1558.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.
   PubMed Web of Science ®Google Scholar
• Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 2017 03;36(1):141–157.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014 Mar;19(3):235–242.
   PubMed Web of Science ®Google Scholar
• Peraldo-Neia C, Scatolini M, Grosso E, et al. Assessment of a High Sensitivity Method for Identification of IDH1 R132x mutations in tumors and plasma of intrahepatic cholangiocarcinoma patients. Cancers (Basel). 2019 Mar;11(4).
   Web of Science ®Google Scholar
• Ishii Y, Sigel C, Lowery MA, et al. AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma [abstract]. Mol Cancer Ther. 2018;17(1 Suppl):A071–A071.
   Google Scholar
• Lowery MA, Burris HA, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711–720.
   PubMed Web of Science ®Google Scholar
• Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precis Oncol. 2018;(2):1–12.
   PubMedGoogle Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II Study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018 Jan;36(3):276–282.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019 Jan;120(2):165–171.
   PubMed Web of Science ®Google Scholar
• Hollebecque A, Borad M, Sahai V, et al. Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations [abstract]. Ann Oncol. 2018;29(suppl_8):viii258.
   Google Scholar
• Chen -Y-Y, Park JO, Su W-C, et al. Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA) [abstract]. Ann Oncol. 2018;29(suppl_8):viii209.
   Google Scholar
• Nakazawa K, Dobashi Y, Suzuki S, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005 Jul;206(3):356–365.
   PubMed Web of Science ®Google Scholar
• Leone F, Cavalloni G, Pignochino Y, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006 Mar;12(6):1680–1685.
   PubMed Web of Science ®Google Scholar
• Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study). Cancer. 2016 Feb;122(4):574–581.
   PubMed Web of Science ®Google Scholar
• Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014 Jul;15(8):819–828.
   PubMed Web of Science ®Google Scholar
• Cai W, Yuan Y, Ge W, et al. EGFR target therapy combined with gemox for advanced biliary tract cancers: a meta-analysis based on RCTs. J Cancer. 2018;9(8):1476–1485.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen C, Yen Y, et al. Chemotherapy for advanced biliary tract carcinoma: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016 Aug;95(33):e4584.
   PubMed Web of Science ®Google Scholar
• Yamashita-Kashima Y, Yoshimura Y, Fujimura T, et al. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. Cancer Chemother Pharmacol. 2019 Apr;83(4):659–671.
   PubMed Web of Science ®Google Scholar
• Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58.
   PubMed Web of Science ®Google Scholar
• Javle MM, Hainsworth JD, Swanton C, et al. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from MyPathway [abstract]. J Clin Oncol. 2017;35(4_suppl):402.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 02;554(7691):189–194.
   PubMed Web of Science ®Google Scholar
• Tan AC, Oh D, Chao Y, et al. Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: a pooled analysis from three phase I studies [abstract]. J Clin Oncol. 2019;37(4_suppl):331.
   Web of Science ®Google Scholar
• Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003 May;52(5):706–712.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug;373(8):726–736.
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Lassen UN, Elez E, et al. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial [abstract]. J Clin Oncol. 2019;37(4_suppl):187.
   Web of Science ®Google Scholar
• Corti F, Nichetti F, Raimondi A, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treat Rev. 2019;72:45–55.
   PubMed Web of Science ®Google Scholar
• Kim RD, Alberts SR, Peña C, et al. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. Br J Cancer. 2018 02;118(4):462–470.
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 02;378(8):731–739.
   PubMed Web of Science ®Google Scholar
• Lim SM, Yoo JE, Lim KH, et al. Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma. Cancer Res Treat. 2017 Jan;49(1):185–192.
   PubMedGoogle Scholar
• Peraldo Neia C, Cavalloni G, Balsamo A, et al. Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. Genes Chromosomes Cancer. 2014 Dec;53(12):1033–1040.
   PubMed Web of Science ®Google Scholar
• Golan T, Raitses-Gurevich M, Kelley RK, et al. Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study. Oncologist. 2017 07;22(7):804–810.
   PubMed Web of Science ®Google Scholar
• Park BK, Paik YH, Park JY, et al. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol. 2006 Apr;29(2):138–142.
   PubMed Web of Science ®Google Scholar
• Demols A, Borbath I, Eynde MVD, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: a randomized double-blinded placebo-controlled phase II trial [abstract]. J Clin Oncol. 2019;37(4_suppl):345.
   Web of Science ®Google Scholar
• Sun W, Patel A, Normolle D, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019 Mar;125(6):902–909.
   PubMed Web of Science ®Google Scholar
• Assenat E, Guimbaud R, Fraisse J, et al. A multicenter phase Ib-IIR trial assessing the activity of regorafenib combined with modified gemcitabine: oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC). J Clin Oncol. 2018;36:e16134–e16134.
   Web of Science ®Google Scholar
• Ikeda M, Sasaki T, Morizane C, et al. A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results [abstract]. Ann Oncol. 2017;28(suppl_5):v246.
   PubMedGoogle Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002 Jun;3(6):415–428.
   PubMed Web of Science ®Google Scholar
• Morine Y, Shimada M, Iwahashi S, et al. Role of histone deacetylase expression in intrahepatic cholangiocarcinoma. Surgery. 2012 Mar;151(3):412–419.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Ohno I, Ueno H, et al. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Invest New Drugs. 2019 02;37(1):109–117.
   PubMed Web of Science ®Google Scholar
• Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2016 08;23(8):2610–2617.
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res. 2016 Jan;22(2):470–478.
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Mancham S, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. J Hepatol. 2019 Jun 11 (Epub ahead of print).
   Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 07;357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• Yuza K, Nagahashi M, Watanabe S, et al. Hypermutation and microsatellite instability in gastrointestinal cancers. Oncotarget. 2017 Dec;8(67):112103–112115.
   PubMedGoogle Scholar
• Javle MM, Murugesan K, Shroff R, et al. Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH) [abstract]. J Clin Oncol. 2019;37(15_suppl):4087.
   Web of Science ®Google Scholar
• Kim RD, Kim DW, Alese OB, et al. A phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC) [abstract]. J Clin Oncol. 2019;37(15_suppl):4097.
   Google Scholar
• Ueno M, Chung HC, Nagrial A, et al. Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase II KEYNOTE-158 study [abstract]. Ann Oncol. 2018;29(suppl_8):viii210.
   Web of Science ®Google Scholar
• Ioka T, Ueno M, Oh D-Y, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC) [abstract]. J Clin Oncol. 2019;37(4_suppl):387.
   Web of Science ®Google Scholar
• Eads JR, Stein S, El-Khoueiry AB, et al. A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC) [abstract]. J Clin Oncol. 2017;35(15_suppl):4075.
   Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018 05;15(5):325–340.
   PubMed Web of Science ®Google Scholar
• Lin J, Shi W, Zhao S, et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing [abstract]. J Clin Oncol. 2018;36(4_suppl):500.
   Web of Science ®Google Scholar
• Kopetz S, Spira AI, Wertheim M, et al. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: preliminary results from a phase I trial [abstract]. J Clin Oncol. 2018;36(4_suppl):764.
   Web of Science ®Google Scholar
• Alnaggar M, Xyu Y, Li J, et al. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J Immunother Cancer. 2019 Feb 8;7(1):36.
   PubMed Web of Science ®Google Scholar
• Guo Y, Feng K, Liu Y, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res. 2018 Mar;24(6):1277–1286.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018 03;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Chan-On W, Nairismägi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013 Dec;45(12):1474–1478.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 May 1;30(5):863–870.
   PubMed Web of Science ®Google Scholar
• Kish M, Chan KK, Perry K, et al. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers [abstract]. J Clin Oncol. 2019;37(4_suppl):247.
   Web of Science ®Google Scholar
• Akahoshi K, Ban D, Kuboki R, et al. Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients. J Gastroenterol Hepatol. 2019 Jun;34(6):1108–1115.
   PubMed Web of Science ®Google Scholar
• Chie EK, Kim BH, Kwon J, et al. Association of adjuvant chemoradiotherapy with survival in patients with resected gallbladder carcinoma: a systematic review and meta-analysis [abstract]. J Clin Oncol. 2018;36(4_suppl):477.
   Web of Science ®Google Scholar
• Yadav S, Xie H, Bin-Riaz I, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis. Eur J Surg Oncol. 2019 Aug;45(8):1432–1438.
   PubMed Web of Science ®Google Scholar